Medpace (MEDP) to Release Quarterly Earnings on Wednesday

Medpace (NASDAQ:MEDP) is expected to be issuing its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect the company to announce earnings of $3.49 per share and revenue of $640.4870 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 23, 2025 at 9:00 AM ET.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.75 earnings per share. On average, analysts expect Medpace to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Medpace Stock Up 1.3%

NASDAQ MEDP opened at $528.07 on Monday. The stock has a market cap of $14.83 billion, a P/E ratio of 39.26, a PEG ratio of 3.31 and a beta of 1.40. The company’s 50-day simple moving average is $492.23 and its 200 day simple moving average is $382.87. Medpace has a twelve month low of $250.05 and a twelve month high of $547.15.

Analyst Upgrades and Downgrades

A number of research firms have commented on MEDP. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research report on Wednesday, July 23rd. Jefferies Financial Group boosted their price target on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research report on Tuesday, September 9th. William Blair restated a “market perform” rating on shares of Medpace in a research report on Wednesday, July 23rd. Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medpace in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $430.60.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 48,487 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares in the company, valued at $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock valued at $74,111,427 in the last three months. 20.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medpace

Large investors have recently modified their holdings of the stock. M&T Bank Corp raised its stake in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the last quarter. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of Medpace by 7.0% during the second quarter. NewEdge Advisors LLC now owns 1,121 shares of the company’s stock worth $352,000 after buying an additional 73 shares during the last quarter. Vident Advisory LLC raised its stake in shares of Medpace by 3.3% during the second quarter. Vident Advisory LLC now owns 3,998 shares of the company’s stock worth $1,255,000 after buying an additional 127 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Medpace by 41.4% during the second quarter. Tower Research Capital LLC TRC now owns 533 shares of the company’s stock worth $167,000 after buying an additional 156 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.